Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 19/20 | 0.67 |
| ▸ | NR3C2 | P08235 | 10/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775343 | 1.00 | NR3C1 (0.67) | NR3C1NR3C2PGR | |
| SCHEMBL1775018 | 1.00 | NR3C1 (0.67) | NR3C1NR3C2PGR | |
| SCHEMBL4817160 | 0.90 | NR3C2 (0.61) | NR3C1NR3C2PGR | |
| SCHEMBL1634191 | 0.85 | NR3C1 (0.58) | NR3C1NR3C2PGR | |
| SCHEMBL6556072 | 0.85 | NR3C1 (0.54) | NR3C1NR3C2PGR | |
| SCHEMBL1775737 | 0.84 | NR3C1 (0.52) | NR3C1NR3C2PGR | |
| SCHEMBL6686671 | 0.84 | NR3C1 (0.68) | NR3C1NR3C2PGR | |
| SCHEMBL4772164 | 0.84 | NR3C1 (0.69) | NR3C1NR3C2 | |
| SCHEMBL4772156 | 0.84 | NR3C1 (0.69) | NR3C1NR3C2 | |
| SCHEMBL13767407 | 0.83 | NR3C1 (0.48) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | US | claimed |
| WO-2004075864-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| EP-2013185-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1844039-B1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AG (DE) | 2009-07-15 | — | — | EP | disclosed |
| US-20090111866-A1 | Novel Compounds | GLAXO WELLCOME HOUSE (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| CN-1334809-A | Non-steroidal anti-inflammatory drugs | SCHERING AG (DE) | 2002-02-06 | — | — | CN | disclosed |
| US-6344454-B1 | CONTRACEPTIVE PREPARATIONS,TREATMENT OF ENDOMETRIOSIS, GYNECOLOGICAL DISORDERS,PREMENSTRUAL SYMPTOMS, MALE BIRTH CONTROL, MALE HRT AND HORMONE THERAPY AND FOR TREATING ANDROLOGICAL DISEASE AGENTS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-05 | — | — | US | disclosed |
| US-6323199-B1 | AROMATIC HETEROCYCLIC HYDROXY AMINES OR AMIDES FOR TREATMENT OF INFLAMMATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
| EP-1133486-A2 | NONSTEROIDAL ANTIINFLAMMATORIES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-19 | — | — | EP | disclosed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| WO-2000032584-A2 | NONSTEROIDAL ANTIINFLAMMATORIES | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-06-08 | — | — | WO | disclosed |
| EP-0986545-A1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998054159-A1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016365-A1 | Nonsteroidal gestagens | NR5A1, GPER1, ESR2 | NR3C1 25/4885NR3C2 32/4885PGR 9/4885 |
| US-20090111866-A1 | Novel Compounds | CCL11, MRGPRX2, LTB4R2 | NR3C1 190/4885NR3C2 271/4885PGR 1312/4885 |
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.